|
| 38058184 | Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. | Haematologica | 2024 |
| 38058184 | Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease. | Haematologica | 2024 |
| 36226495 | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. | Haematologica | 2023 |
| 36226495 | A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. | Haematologica | 2023 |
| 37647654 | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. | Blood | 2023 |
| 36519323 | CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. | Haematologica | 2023 |
| 36587740 | Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age â¿¥55 Years. | Transplant Cell Ther | 2023 |
| 37084383 | Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. | Blood | 2023 |
| 37014667 | Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. | Clin Cancer Res | 2023 |
| 36808557 | An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. | Curr Oncol Rep | 2023 |
| 37379495 | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | J Clin Oncol | 2023 |
| 36744656 | Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. | Leuk Lymphoma | 2023 |
| 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 37354804 | Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia. | Leuk Res | 2023 |
| 36722402 | The clinical impact of the molecular landscape of acute myeloid leukemia. | Haematologica | 2023 |
| 36526260 | Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. | Transplant Cell Ther | 2023 |
| 37647654 | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. | Blood | 2023 |
| 37354804 | Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia. | Leuk Res | 2023 |
| 37084383 | Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. | Blood | 2023 |
| 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 |
| 37014667 | Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. | Clin Cancer Res | 2023 |
| 37379495 | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | J Clin Oncol | 2023 |
| 36722402 | The clinical impact of the molecular landscape of acute myeloid leukemia. | Haematologica | 2023 |
| 36587740 | Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age â¿¥55 Years. | Transplant Cell Ther | 2023 |
| 36519323 | CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. | Haematologica | 2023 |
| 36808557 | An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. | Curr Oncol Rep | 2023 |
| 36744656 | Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. | Leuk Lymphoma | 2023 |
| 36526260 | Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. | Transplant Cell Ther | 2023 |
| 34134554 | Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. | J Oncol Pharm Pract | 2022 |
| 36227747 | By any other name⿿⿦. | Blood | 2022 |
| 35637252 | Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. | Blood Cancer J | 2022 |
| 35379077 | Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. | Leuk Lymphoma | 2022 |
| 36150050 | Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. | Blood Adv | 2022 |
| 35849791 | Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia. | J Clin Oncol | 2022 |
| 34134554 | Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. | J Oncol Pharm Pract | 2022 |
| 34350585 | Updates on targeted therapies for acute myeloid leukaemia. | Br J Haematol | 2022 |
| 34348451 | Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. | Haematologica | 2022 |
| 35179961 | The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. | Sci Adv | 2022 |
| 35158092 | Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. | Transplant Cell Ther | 2022 |
| 35130342 | Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. | Blood Adv | 2022 |
| 35142153 | Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. | Haematologica | 2022 |
| 35081255 | Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. | Blood | 2022 |
| 34750086 | Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. | Clin Lymphoma Myeloma Leuk | 2022 |
| 35379077 | Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. | Leuk Lymphoma | 2022 |
| 35637252 | Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. | Blood Cancer J | 2022 |
| 35849791 | Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia. | J Clin Oncol | 2022 |
| 36150050 | Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. | Blood Adv | 2022 |
| 36227747 | By any other name⿿⿦. | Blood | 2022 |
| 35158092 | Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. | Transplant Cell Ther | 2022 |
| 35130342 | Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. | Blood Adv | 2022 |